Moderna's second quarter revenue of $145 million beats estimates amid a key pipeline setback.

Moderna reported second quarter 2026 revenue of $145 million, up from $142 million in the prior-year period, alongside a net loss per share of $1.97, an improvement from a loss of $2.13 per share a year ago. The company beat revenue expectations but was in-line with EPS estimates.

Key Highlights

• The company reiterated its full-year 2026 guidance, targeting up to 10% revenue growth compared to 2025.
• Moderna announced its norovirus vaccine candidate, mRNA-1403, did not meet statistical criteria for early success in its Phase 3 interim analysis.
• Full-year 2026 operating expense guidance was lowered by approximately $200 million, and the projected year-end cash and investments balance was raised to a range of $4.7 billion to $5.2 billion.
• The company expects a potential U.S. approval for its seasonal influenza vaccine, mFLUSIVA, with a PDUFA date set for August 5, 2026.